What Happened? Shares of medication company Viatris (NASDAQ:VTRS) jumped 3% in the morning session after it received approval ...

Viatris (NASDAQ:VTRS) announced on Monday that the U.S. FDA has approved its Iron Sucrose Injection, USP, as a generic ...

Viatris Inc (NASDAQ:VTRS) saw its stock increase by 2.6% after the U.S. Food and Drug Administration approved its Iron ...

Medication company Viatris (NASDAQ:VTRS) reported in Q2 CY2025, but sales fell by 5.6% year on year to $3.58 billion. The ...

Investing.com -- Viatris Inc (NASDAQ: VTRS) stock rose 2.6% following the U.S. Food and Drug Administration’s approval of the company’s Iron Sucrose Injection, USP, the first generic version of ...

Q2 2025 Earnings Call Transcript August 7, 2025 Viatris Inc. beats earnings expectations. Reported EPS is $0.62, expectations ...

The week-ending August 8 saw 20 companies in the healthcare sector report their quarterly earnings. With the earnings season ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q1, starting with ...

Medication company Viatris (NASDAQ:VTRS) will be reporting earnings this Thursday before market open. Here’s what investors ...

Viatris (VTRS) is set to announce Q2 earnings amid EPS and revenue declines. Learn about its recent trials, stock dip, and Wall Street's Hold rating.

(RTTNews) - Viatris Inc. (VTRS) announced that a randomized, double-masked, vehicle-controlled, Phase 3 study to evaluate the efficacy and safety of pimecrolimus 0.3% ophthalmic ointment in ...

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...